Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian E Serfling

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Molecular Imaging and Biology|June 21, 2026
Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer ModelsPhilipp E Hartrampf, Sebastian E Serfling, Natalie Hasenauer, et al.
Nuklearmedizin. Nuclear Medicine|February 25, 2026
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and NeckSophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, et al.
Molecular Imaging and Biology|January 4, 2024
Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological StudiesYohji Matsusaka, Rudolf A Werner, Sebastian E Serfling, et al.
Clinical Nuclear Medicine|March 17, 2023
Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine TumorAlexander Weich, Sebastian E Serfling, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 11, 2022
CXCR4-targeted molecular imaging after severe SARS-Cov-2 infectionAlessandro Lambertini, Philipp E Hartrampf, Takahiro Higuchi, et al.
Seminars in Nuclear Medicine|May 26, 2023
Role of Functional SPECT and PET in Renal EmergenciesTakahiro Higuchi, Philipp E Hartrampf, Andreas K Buck, et al.
Annals of Nuclear Medicine|October 27, 2023
Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapyKerstin Michalski, Aleksander Kosmala, Rudolf A Werner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2022
CXCR4-targeted theranostics in oncologyAndreas K Buck, Sebastian E Serfling, Thomas Lindner, et al.
Cancers|September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient OutcomePhilipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
Endocrine|December 22, 2023
[<sup>18</sup>F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patientsYingjun Zhi, Takahiro Higuchi, Stephan Hackenberg, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Molecular Imaging and Biology|June 21, 2026
Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer ModelsPhilipp E Hartrampf, Sebastian E Serfling, Natalie Hasenauer, et al.
Nuklearmedizin. Nuclear Medicine|February 25, 2026
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and NeckSophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, et al.
Molecular Imaging and Biology|January 4, 2024
Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological StudiesYohji Matsusaka, Rudolf A Werner, Sebastian E Serfling, et al.
Clinical Nuclear Medicine|March 17, 2023
Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine TumorAlexander Weich, Sebastian E Serfling, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 11, 2022
CXCR4-targeted molecular imaging after severe SARS-Cov-2 infectionAlessandro Lambertini, Philipp E Hartrampf, Takahiro Higuchi, et al.
Seminars in Nuclear Medicine|May 26, 2023
Role of Functional SPECT and PET in Renal EmergenciesTakahiro Higuchi, Philipp E Hartrampf, Andreas K Buck, et al.
Annals of Nuclear Medicine|October 27, 2023
Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapyKerstin Michalski, Aleksander Kosmala, Rudolf A Werner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2022
CXCR4-targeted theranostics in oncologyAndreas K Buck, Sebastian E Serfling, Thomas Lindner, et al.
Cancers|September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient OutcomePhilipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
Endocrine|December 22, 2023
[<sup>18</sup>F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patientsYingjun Zhi, Takahiro Higuchi, Stephan Hackenberg, et al.
Pageof 8